TY  - JOUR
AU  - Grosu, Anca-Ligia
AU  - Weber, Wolfgang A
AU  - Graf, Erika
AU  - Mix, Michael
AU  - Nestle, Ursula
AU  - Schimek-Jasch, Tanja
AU  - Wiehle, Rolf
AU  - Mader, Irina
AU  - Würtemberger, Urs
AU  - Langen, Karl-Josef
AU  - Niyazi, Maximilian
AU  - Paulsen, Frank
AU  - König, Liane
AU  - Giordano, Frank Anton
AU  - Spehl, Irina
AU  - Bernhardt, Denise
AU  - Schymalla, Markus M
AU  - Pöttgen, Christoph
AU  - Semrau, Sabine
AU  - Brunner, Thomas
AU  - Hültenschmidt, Beatrix
AU  - Krause, Bernd Joachim
AU  - Ciernik, Ilja Frank
AU  - Beck, Jürgen
AU  - Baumert, Brigitta G
AU  - Meyer, Philipp T
AU  - Urbach, Horst
AU  - Popp, Ilinca
TI  - O-(2-[18F]fluoroethyl)-L-tyrosine-PET-guided versus contrast-enhanced T1-weighted MRI-guided re-irradiation in patients with recurrent glioblastoma (GLIAA/NOA-10 ARO2013-01): a multicentre, open-label, randomised trial.
JO  - The lancet / Oncology
VL  - nn
SN  - 1470-2045
CY  - London
PB  - The Lancet Publ. Group
M1  - DKFZ-2025-03035
SP  - nn
PY  - 2025
N1  - epub
AB  - O-(2-[18F]fluoroethyl)-L-tyrosine (FET)-PET has a higher specificity than contrast-enhanced T1-weighted MRI (CE-T1MRI) in diagnosing recurrent glioblastoma. We aimed to evaluate whether a FET-PET-based target volume delineation, compared with CE-T1MRI, improves outcomes in patients with recurrent glioblastoma scheduled for re-irradiation.GLIAA was a multicentre, open-label, parallel randomised study done in 15 radiation oncology centres in Germany. Patients aged 18 years or older with a Karnofsky performance score greater than 60
LB  - PUB:(DE-HGF)16
C6  - pmid:41429128
DO  - DOI:10.1016/S1470-2045(25)00642-4
UR  - https://inrepo02.dkfz.de/record/307436
ER  -